Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial

Anatol Nacu,1 Robert Hoerr21Clinical Psychiatry Hospital, State University of Medicine and Pharmacy Nicolae Testemiţanu, Chişinău, Republic of Moldova; 2Clinical Research Department, Dr Willmar Schwabe GmbH and Co. KG, Karlsruhe, GermanyBackground: In randomized controlled trials, Ginkgo biloba extr...

Full description

Bibliographic Details
Main Authors: Nacu A, Hoerr R
Format: Article
Language:English
Published: Dove Medical Press 2016-01-01
Series:Open Access Journal of Clinical Trials
Subjects:
Online Access:https://www.dovepress.com/neuropsychiatric-symptoms-in-dementia-and-the-effects-of-ginkgo-biloba-peer-reviewed-article-OAJCT
_version_ 1811306887300251648
author Nacu A
Hoerr R
author_facet Nacu A
Hoerr R
author_sort Nacu A
collection DOAJ
description Anatol Nacu,1 Robert Hoerr21Clinical Psychiatry Hospital, State University of Medicine and Pharmacy Nicolae Testemiţanu, Chişinău, Republic of Moldova; 2Clinical Research Department, Dr Willmar Schwabe GmbH and Co. KG, Karlsruhe, GermanyBackground: In randomized controlled trials, Ginkgo biloba extract EGb 761® has proven to be effective in the treatment of dementia.Trial registration: Clinical-Trials.ru 390378.Patients and methods: In pre-specified descriptive analyses of data from a recently published trial, we examined the effects of EGb 761® on specific neuropsychiatric symptoms. In a 24-week, double-blind, multi-center trial, 410 outpatients with mild to moderate dementia and clinically significant neuropsychiatric symptoms were enrolled and randomized to receive 240 mg/day EGb 761® or placebo. The Neuropsychiatric Inventory composite score and the SKT short cognitive performance test were prospectively defined as co-primary outcomes; caregiver distress scores and single item scores were prospectively defined as secondary outcomes.Results: Post-baseline efficacy data were available for 402 patients included in the full analysis set. Neuropsychiatric Inventory composite and caregiver distress scores improved significantly more under EGb 761® treatment than under placebo (P<0.001). Composite and caregiver distress scores of anxiety, apathy, and disturbances of sleep and nighttime behavior, as well as caregiver distress scores of depression and aberrant motor behavior, were improved most markedly by EGb 761® (P<0.05 vs placebo).Conclusion: EGb 761® at daily doses of 240 mg alleviated neuropsychiatric symptoms of dementia and reduced related caregiver distress.Keywords: dementia, neuropsychiatric symptoms, Ginkgo biloba, EGb 761®, randomized controlled trial 
first_indexed 2024-04-13T08:53:31Z
format Article
id doaj.art-b346d58e842346199a419d4a33915818
institution Directory Open Access Journal
issn 1179-1519
language English
last_indexed 2024-04-13T08:53:31Z
publishDate 2016-01-01
publisher Dove Medical Press
record_format Article
series Open Access Journal of Clinical Trials
spelling doaj.art-b346d58e842346199a419d4a339158182022-12-22T02:53:23ZengDove Medical PressOpen Access Journal of Clinical Trials1179-15192016-01-012016Issue 11625264Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trialNacu AHoerr RAnatol Nacu,1 Robert Hoerr21Clinical Psychiatry Hospital, State University of Medicine and Pharmacy Nicolae Testemiţanu, Chişinău, Republic of Moldova; 2Clinical Research Department, Dr Willmar Schwabe GmbH and Co. KG, Karlsruhe, GermanyBackground: In randomized controlled trials, Ginkgo biloba extract EGb 761® has proven to be effective in the treatment of dementia.Trial registration: Clinical-Trials.ru 390378.Patients and methods: In pre-specified descriptive analyses of data from a recently published trial, we examined the effects of EGb 761® on specific neuropsychiatric symptoms. In a 24-week, double-blind, multi-center trial, 410 outpatients with mild to moderate dementia and clinically significant neuropsychiatric symptoms were enrolled and randomized to receive 240 mg/day EGb 761® or placebo. The Neuropsychiatric Inventory composite score and the SKT short cognitive performance test were prospectively defined as co-primary outcomes; caregiver distress scores and single item scores were prospectively defined as secondary outcomes.Results: Post-baseline efficacy data were available for 402 patients included in the full analysis set. Neuropsychiatric Inventory composite and caregiver distress scores improved significantly more under EGb 761® treatment than under placebo (P<0.001). Composite and caregiver distress scores of anxiety, apathy, and disturbances of sleep and nighttime behavior, as well as caregiver distress scores of depression and aberrant motor behavior, were improved most markedly by EGb 761® (P<0.05 vs placebo).Conclusion: EGb 761® at daily doses of 240 mg alleviated neuropsychiatric symptoms of dementia and reduced related caregiver distress.Keywords: dementia, neuropsychiatric symptoms, Ginkgo biloba, EGb 761®, randomized controlled trial https://www.dovepress.com/neuropsychiatric-symptoms-in-dementia-and-the-effects-of-ginkgo-biloba-peer-reviewed-article-OAJCTdementianeuropsychiatric symptomsGinkgo bilobaEGb 761®randomized controlled trial
spellingShingle Nacu A
Hoerr R
Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
Open Access Journal of Clinical Trials
dementia
neuropsychiatric symptoms
Ginkgo biloba
EGb 761®
randomized controlled trial
title Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
title_full Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
title_fullStr Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
title_full_unstemmed Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
title_short Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial
title_sort neuropsychiatric symptoms in dementia and the effects of ginkgo biloba extract egb 761 reg treatment additional results from a 24 week randomized placebo controlled trial
topic dementia
neuropsychiatric symptoms
Ginkgo biloba
EGb 761®
randomized controlled trial
url https://www.dovepress.com/neuropsychiatric-symptoms-in-dementia-and-the-effects-of-ginkgo-biloba-peer-reviewed-article-OAJCT
work_keys_str_mv AT nacua neuropsychiatricsymptomsindementiaandtheeffectsofginkgobilobaextractegb761regtreatmentadditionalresultsfroma24weekrandomizedplacebocontrolledtrial
AT hoerrr neuropsychiatricsymptomsindementiaandtheeffectsofginkgobilobaextractegb761regtreatmentadditionalresultsfroma24weekrandomizedplacebocontrolledtrial